... P: Estimating the world cancer burden: Globocan 2000 Int J Cancer 2001, 94:153-156 Non -small CellLungCancer Collaborative Group: Chemotherapy in non smallcelllung cancer: a meta-analysis ... Translational Medicine 2008, 6:65 Background Lungcancer remains the leading cause of cancer- related mortality in the western world Non -small celllungcancer (NSCLC) accounts for approximately ... cisplatin-teniposide in patients with advanced non -small- celllungcancer The European Organization for Research and Treatment of CancerLungCancer Cooperative Group J Clin Oncol 1998, 16:2133-2141...
... may act as a risk marker of lungcancer in Taiwan Cancer 2003, 97:1558-1563 11 Klein F, Amin Kotb WF, Petersen I: Incidence of human papilloma virus in lungcancerLungCancer 2009, 65:13-18 12 ... http://www.translational-medicine.com/content/9/1/2 Normal LungSmallCellLungCancer Figure Human SCLC hierarchical clustering of the significantly deregulated genes Analysis show human normal control lung tissues and SCLC samples ... HPVs in Asian lungcancer is 35.7% The authors concluded that HPV may be the second leading cause of lungcancer after cigarette smoking Although studies of viral-related lungcancer have been...
... marker expression in tumor cells versus stromal cells in non smallcelllungcancer Clin Cancer Res 2007, 13:6649-57 World Health Organization: Histological Typing of Lung and Pleural Tumours Geneva, ... in non -small celllungcancer Clin Cancer Res 2008, 14:5220-7 Andersen S, Eilertsen M, Donnem T, et al: Diverging prognostic impacts of hypoxic markers according to NSCLC histology LungCancer ... adjuvant chemotherapy after complete resection of non -small celllung carcinoma Cancer Res 2010, 70:8288-98 Goldstraw P: The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol 2009, 4:671-3...
... Staging of smallcell and non -small celllungcancer University of Iowa Virtual Hospital; 1999 Hopwood P, Stephens RJ: Symptoms at presentation for treatment in patients with lung cancer: Implications ... Research and Treatment of Cancer Quality-of-Life Questionnaire -Lung Cancer- 17 items; EQ-5D: EuroQoL-5 Dimensions; HRQL: Healthrelated Quality of Life; NSCLC: Non -Small CellLung Cancer; SF-36: Short-Form ... Lung Trial in Non -Small- CellLungcancer Journal of Clinical Oncology 2005, 30:7417-7427 Silvestri G, Pritchard R, Welch HG: Preferences for chemotherapy in patients with advanced non -small cell...
... expression in non -small celllungcancer Is correlated with survival Clin Cancer Res 2001; 7(7): 1850-5 93 Cappuzzo F, Gregorc V, Rossi E, et al Gefitinib in pretreated non -small- celllungcancer (NSCLC): ... ZD1839) in non -small- celllungcancer Br J Cancer 2004; 91(2): 208-12 89 Bailey R, Kris M, Wolf M Gefitinib (Iressa, ZD 1839) monotherapy for pretreated advanced non -small celllungcancer in IDEAL ... expression in non -small celllungcancer to long term survival Br J Cancer 1993; 68(1): 162-5 87 Meert AP, Martin B, Delmotte P, et al The role of EGF-R expression on patient survival in lung cancer: a...
... non -small- celllung cancer: a meta-analysis JAMA 2004, 292:470-84 Mattson KV, Abratt RP, ten Velde G, Krofta K: Docetaxel as neoadjuvant therapy for radically treatable stage III non -small- celllung ... docetaxel/cisplatin in patients with advanced non -small- celllung cancer: preliminary analysis of a multicenter, randomized phase III study Clin LungCancer 2003, 4:288-93 Lilenbaum RC, Herndon JE, ... Holland JC, Green MR: Single-agent versus combination chemotherapy in advanced non -small- celllung cancer: the cancer and leukemia group B (study 9730) J Clin Oncol 2005, 23:190-6 Heys SD, Hutcheon...
... non -small- celllungcancer Int J Radiat Oncol Biol Phys 2002, 52:382-389 Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R: The role of radiotherapy in treatment of stage I non -small celllungcancer ... non -small- celllung cancer: clinical implications Radiother Oncol 2010, 94:1-11 Chen Y, Guo W, Lu Y, Zou B: Dose-individualized stereotactic body radiotherapy for T1-3N0 non -small celllung cancer: ... patients) For all 124 patients, the overall survival (OAS) rate was 71%, the cause-specific survival (CSS) rate was 87%, and the progression-free survival (PFS) rate was 60% at years (Figure 1) The...
... Non -Small- CellLung Cancer: A Systematic Review and Pooled Analysis J Clin Oncol 2008, 26:1142-1147 15 Pfannschmidt J, Dienemann H: Surgical Treatment of Oligometastatic Non -Small CellLungCancer ... DD: Number of Metastatic Sites is a Strong Predictor of Survival in Patients with Nonsmall CellLungCancer With or Without Brain Metastases Cancer 2009, 115:2930-2938 doi:10.1186/1748-717X-6-80 ... Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S: Prognostic factors for survival in Stage III non -small- cell- lungcancer treated with definitive radiation therapy: impact of tumor volume IJROBP...
... for stage I non -small celllung cancer: a 13-year analysis Ann Thorac Surg 2006, 82:408-415 Strand TE, Rostad H, Moller B, Norstein J: Survival after resection for primary lung cancer: a population ... Non -small CellLungCancer Int J Radat Oncol Biol Phys 2007, 69:S46-S47 Hiraoka M, Ishikura S: A Japan clinical oncology group trial for stereotactic body radiation therapy of non -small celllung ... non -small cellLungcancer (ROSEL, ClinicalTrials.gov ID = NCT00687986) has been opened for accrual in August 2008 The study is initiated by the VU medical centre Amsterdam and the Dutch Lung Cancer...
... chemoradiotherapy for limited-disease smallcelllungcancer (Figure 1) The primary endpoint of JCOG 0202 was overall survival and the secondary endpoints included disease-free survival and the toxicity ... whether RT with carboplatin would result in longer survival than RT alone in elderly patients with unresectable stage III non -small celllung cancer; however, due to excessive serious adverse ... responders Figure of Schema JCOG 0202 Schema of JCOG 0202 Abbreviations LD-SCLC, limiteddisease smallcelllung cancer; PS, performance status; EP, etoposide; CDDP, cisplatin; XRT, thoracic radiotherapy;...
... III non -small- celllungcancer Int J Radiat Oncol Biol Phys 2008, 71:139-144 Siker ML, Tome WA, Mehta MP: Tumor volume changes on serial imaging with megavoltage CT for non -small- celllungcancer ... TH, Langen KM: Serial megavoltage CT imaging during external beam radiotherapy for non -small- celllung cancer: observations on tumor regression during treatment Int J Radiat Oncol Biol Phys 2005, ... Assessment of gross tumor volume regression and motion changes during radiotherapy for nonsmall -cell lungcancer as measured by four-dimensional computed tomography Int J Radiat Oncol Biol Phys...
... peripheral stage I non -small celllungcancerLungCancer 1999, 26:137-142 Slotman BJ, Antonisse IE, Njo KH: Limited field irradiation in early stage (T1-2N0) non -small celllungcancer Radiother Oncol ... non -small- celllungcancer (NSCLC) Int J Radiat Oncol Biol Phys 2003, 56:335-341 Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M: Stereotactic radiotherapy for primary lungcancer ... stage I non -small celllungcancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner Lung Cancer...
... escalation in non -small- celllungcancer Int J Radiat Oncol Biol Phys 2001, 49:23-33 Abratt RP, Bogart JA, Hunter A: Hypofractionated radiation for non -small celllungcancerLungCancer 2002, 36:225-33 ... overall survival rates are 78% and 56%, cancer specific survival rates (CSS) are 90% and 74% (Figure 3), and local relapse free survival rates are 93% and 76% respectively Median overall survival ... non -small celllungcancer Int J Radiat Oncon Biol Phys 2002, 52:1047-57 Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R: The role of radiation therapy in treatment of stage I non -small cell lung...
... chemoradiotherapy in non -small celllungcancer (Review) In The Cochrane Library Volume Wiley; 2005:1-37 Vokes EE: Optimal therapy for unresectable stage III nonsmall -cell lungcancer J Clin Oncol ... stage I Nonsmall celllung carcinoma Cancer 2004, 101:1623-1631 Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J: Acute esophageal toxicity in non -small celllungcancer patients ... vinorelbine in patients with locally advanced non -small- celllungcancer A phase II trial conducted by the Groupe Francais de PneumoCancerologie (GFPC) LungCancer 2005, 47:395-404 Vokes E, Herndon J,...
... The Japanese Joint Committee of LungCancer Registry Prognosis of 6644 resected non -small celllung cancers in Japan: a Japanese lungcancer registry study LungCancer 2005, 50:227-34 11 Andre ... locally advanced non -small celllungcancer in Japan Int J Clin Oncol 2008, 13:112-6 Farray D, Mirkovic N, Albain KS: Multimodality therapy for stage III nonsmall -cell lungcancer J Clin Oncol ... patients with non -small celllungcancer J Thorac Oncol 2010, 5:825-9 Ou SH, Zell JA: Validation study of the proposed IASLC staging revisions of the T4 and M non -small celllungcancer descriptors...
... 157,300 deaths from lungcancer [4] Lungcancer has traditionally been dichotomized into two groups based on the histological features of the tumor: smallcell and non -small celllungcancer NSCLC is ... with non -small celllungcancer comprise the majority of cases annotated within the database Other cancers contained in the database include smallcelllung cancer, mesothelioma, esophageal cancer, ... SEER Cancer Statistics Review, 1975-2007 National Cancer Institute Bethesda, MD; [http://seer .cancer. gov/csr/1975_2007] Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non -small celllung cancer: ...